Upcoming Live Activities

Please join in on any of these upcoming live activities. Details regarding participation are found within the activity description.

Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care

1.50 hr(s) | CME , MOC , ABIM

Specialty: CLL , Chronic Lymphocytic Leukemia

Therapeutic Area(s): Hematology , Oncology

Release Date: June 14, 2021

Expiration Date: June 14, 2021

Location: Live Webcast

Continuous or fixed-duration therapy with targeted agents, including BTK and BCL-2 inhibitors, is the new standard for management of chronic lymphocytic leukemia (CLL). New clinical questions that are pushing the boundaries of patient care in CLL include how clinicians can select the optimal regimen for a given patient by choosing between effective targeted strategies or within potent drug classes, whether targeted combinations can displace immunochemotherapy as a potentially curative option in good-risk patients, and the role of novel combination approaches in CLL. This Clinical Consults CME/MOC-certified live web broadcast, developed in collaboration with the CLL Society, will pair compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel will explore important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. This unique event promises to map the current boundaries of modern CLL care and illustrate how innovative therapeutics are pushing beyond to achieve better outcomes for patients.

Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple‐Negative Breast Cancer

1.50 hr(s) | CME , MOC , ABIM , ABPath , CC , ABS

Specialty: Breast Cancer

Therapeutic Area(s): Oncology

Release Date: June 10, 2021

Expiration Date: June 10, 2021

Location: Live Webcast

Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades.

New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices

1.50 hr(s) | CME , NCPD , CPE , ABIM

Specialty: CLL , Chronic Lymphocytic Leukemia

Therapeutic Area(s): Hematology , Oncology

Release Date: June 9, 2021

Expiration Date: June 9, 2021

Location: Live Webcast

The era of immunochemotherapy as a cornerstone of therapy for chronic lymphocytic leukemia (CLL) has been surpassed by the rapid emergence of novel therapeutics—most prominently by the Bruton’s tyrosine kinase (BTK) inhibitor agent class. First- and second-generation BTK inhibitors are effective as monotherapy, appear to be useful in combination with other agents, and are active in many different settings—from treatment naïve to relapsed disease, and in populations unable to tolerate first-generation agents. The central question now is how best to navigate a wider range of choices to develop the best possible treatment for a given patient.

Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management

1.50 hr(s) | CME , NCPD , CPE , MOC , ABIM

Specialty: Basal Cell Carcinoma

Therapeutic Area(s): Oncology

Release Date: June 4, 2021

Expiration Date: June 4, 2021

Location: Live Webcast

Basal cell carcinoma (BCC) is a commonly occurring skin malignancy that is easily treatable with surgery and/or radiation when detected at an early stage. However, advanced disease is typically associated with a poor prognosis and is often more challenging to treat, even with targeted agents (because of adverse events and the potential for acquired resistance). Advances in the understanding of BCC pathogenesis first suggested a role for immunotherapy via PD-1 blockade, and follow-up research has led to regulatory approval of immune treatment, including in patients who have progressed on or are unable to receive hedgehog pathway inhibitors. This “Seminars and Tumor Board” live web broadcast will provide an expert-led tour of the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures will be linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly illustrate how oncologists can adapt their current practice and offer the power of immune-based treatment to patients with BCC. Register today to join us!

BLOOD CANCER CARE & COVID-19: YOUR QUESTIONS ANSWERED

1.50 hr(s) | No CE Offered , Patient Education

Specialty: Other Learner type

Therapeutic Area(s): Hematology , COVID

Release Date: April 8, 2021

Expiration Date: April 8, 2021

Location: Webinar

Join us for this free 90 minute patient education webinar to be held on April 8, 2021 from 7:00pm to 8:30pm when Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society, speaks with Dr. Catriona Jamieson and Dr. Derrick Rossi. Participants will also learn about support resources available through LLS.

Advances in Treatment for Chronic Lymphocytic Leukemia (CLL)

1.50 hr(s) | No CE Offered , Patient Education

Specialty: Other Learner type

Therapeutic Area(s): Hematology , Chronic Lympoblastic Leukemia

Release Date: April 7, 2021

Expiration Date: April 7, 2021

Location: TeleWeb

This telephone and web presentation for patients and caregivers will occur on April 7, 2021 from 1:00 pm to 2:30 pm Eastern Time.

1 2
Copy link
Powered by Social Snap